Felixvet Expands Companion Animal Portfolio with Clindamycin Hydrochloride Tablets

Kansas City, Mo. — July 7, 2026 — Felixvet Inc. today announced the addition of Clindamycin Hydrochloride Tablets to its growing product portfolio. The product received approval from the U.S. Food and Drug Administration (FDA) on June 27, 2025 and is indicated for the treatment of skin infections, wounds and abscesses, dental infections, and osteomyelitis in dogs caused by susceptible bacterial organisms.

“Veterinarians manage bacterial infections every day, and they need treatment options they can trust and prescribe with confidence,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels at Felixvet. “The addition of Clindamycin Hydrochloride Tablets expands access to an important antimicrobial while supporting the practical needs of veterinary teams and pet owners.”

Product Details

Clindamycin Hydrochloride Tablets provide veterinarians with an FDA-approved, bioequivalent option for the treatment of select bacterial infections in dogs, including skin infections, deep wounds and abscesses, dental infections, and osteomyelitis.

Available configurations include:

• 25 mg tablets – 400-count bottles 
• 75 mg tablets – 200-count bottles 
• 150 mg tablets – 100-count bottles 

Each tablet is scored to support accurate dosing and administration and is therapeutically equivalent to the pioneer drug.

“We’re focused on building a portfolio around the products veterinarians use every day,” added Lauren Landolph. “Clindamycin Hydrochloride Tablets are an important addition to that strategy and reflect our commitment to delivering trusted veterinary treatment options.”

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is focused on developing and commercializing high-quality, bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products throughout North America following approval by the U.S. Food and Drug Administration and Health Canada.

Focused exclusively on animal health, Felixvet has established research, development, manufacturing, and commercial capabilities designed to support the evolving needs of veterinary medicine. The company continues to expand its portfolio of FDA-approved pharmaceuticals, providing veterinarians with trusted treatment options across the therapeutic categories they prescribe every day. 

Felixvet aims to be the first truly global generic companion animal pharmaceutical company serving the world’s leading veterinary markets while making high-quality, bioequivalent medicines more accessible to veterinarians, pet owners, and the animals they care for.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com